C. Lindsay DeVane
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
C. Lindsay DeVane has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
John S. Markowitz
9 shared publicationsDavid W. Boulton
Laboratory of Drug Disposition and Pharmacogenetics, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, USA
6 shared publicationsJennifer L. Donovan
Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston South Carolina
6 shared publicationsJun-Sheng Wang
Laboratory of Drug Disposition and Pharmacogenetics, Department of Pharmaceutical Sciences, Medical University of South Carolina, Charleston, SC, USA
5 shared publicationsPharm D
5 shared publicationsS. Craig Risch
5 shared publications
Latest Publications
- 12 August 2025
- Published by MedWorks Media in Psychopharmacology Bulletin
- Vol. 36 (2) , 40-50
Psychoactive Drug Interactions With Pharmacotherapy for Diabetes
Diabetes is a common endocrine disorder increasingly encountered in patients requiring treatment with psychoactive drugs. The pharmacotherapy options for diabetes have expanded in recent years and now include 14 oral hypoglycemic drugs from five pharmacologic classes, as well as insulin. The diversity of drugs raises the need for clinicians to be aware of potential drug interactions. Fortunately, few drug interactions of major clinical significance involving psychoactive drugs with oral hypoglycemics have been described in the medical literature. The newer drugs for treatment of type 2 diabetes are discussed, and considerations are given for avoiding or minimizing drug interactions when prescribing psychoactive drugs to patients with diabetes. Psychopharmacology Bulletin. 2002;36(2):40-52
- 12 August 2025
- Published by MedWorks Media in Psychopharmacology Bulletin
- Vol. 36 (2) , 40-50
Psychoactive Drug Interactions With Pharmacotherapy for Diabetes
Diabetes is a common endocrine disorder increasingly encountered in patients requiring treatment with psychoactive drugs. The pharmacotherapy options for diabetes have expanded in recent years and now include 14 oral hypoglycemic drugs from five pharmacologic classes, as well as insulin. The diversity of drugs raises the need for clinicians to be aware of potential drug interactions. Fortunately, few drug interactions of major clinical significance involving psychoactive drugs with oral hypoglycemics have been described in the medical literature. The newer drugs for treatment of type 2 diabetes are discussed, and considerations are given for avoiding or minimizing drug interactions when prescribing psychoactive drugs to patients with diabetes. Psychopharmacology Bulletin. 2002;36(2):40-52
- 12 August 2025
- Published by MedWorks Media in Psychopharmacology Bulletin
- Vol. 35 (2) , 50-61
Charleston Antidepressant Drug Interactions Surveillance Program (CADISP)
A prospective antidepressant drug interaction surveillance program was established and collected data for over 4 years in Charleston, SC (Charleston Antidepressant Drug Interactions Surveillance Program, CADISP). One hundred and seventy patients were enrolled. The plasma concentrations and/or clinical effects of drug combinations were monitored in psychiatric patients who received therapy with a selective serotonin reuptake inhibitor (SSRI) or one of the other newer antidepressants (nefazodone, venlafaxine) when combined with other drugs metabolized by the cytochrome P-450 (CYP) enzyme system. Patient data were evaluated to estimate the occurrence and significance of antidepressant-induced metabolic drug interactions. Plasma drug concentrations in the presence and absence of treatment with an antidepressant served as the primary assessment variable. Contrary to the hypothesis that pharmacokinetic drug–drug interactions occur but go undetected, little evidence was found for occultly occurring drug interactions with newer antidepressants. The presence of commonly predicted drug interactions was documented. These data do not eliminate the need for caution when prescribing antidepressants with the potential for causing metabolic interactions, but do help allay the fear that such interactions are highly prevalent and routinely hazardous.
- 12 August 2025
- Published by MedWorks Media in Psychopharmacology Bulletin
- Vol. 35 (2) , 50-61
Charleston Antidepressant Drug Interactions Surveillance Program (CADISP)
A prospective antidepressant drug interaction surveillance program was established and collected data for over 4 years in Charleston, SC (Charleston Antidepressant Drug Interactions Surveillance Program, CADISP). One hundred and seventy patients were enrolled. The plasma concentrations and/or clinical effects of drug combinations were monitored in psychiatric patients who received therapy with a selective serotonin reuptake inhibitor (SSRI) or one of the other newer antidepressants (nefazodone, venlafaxine) when combined with other drugs metabolized by the cytochrome P-450 (CYP) enzyme system. Patient data were evaluated to estimate the occurrence and significance of antidepressant-induced metabolic drug interactions. Plasma drug concentrations in the presence and absence of treatment with an antidepressant served as the primary assessment variable. Contrary to the hypothesis that pharmacokinetic drug–drug interactions occur but go undetected, little evidence was found for occultly occurring drug interactions with newer antidepressants. The presence of commonly predicted drug interactions was documented. These data do not eliminate the need for caution when prescribing antidepressants with the potential for causing metabolic interactions, but do help allay the fear that such interactions are highly prevalent and routinely hazardous.
- 12 August 2025
- Published by MedWorks Media in Psychopharmacology Bulletin
- Vol. 37 (4) , 116-131
Risperidone in the Management of Psychiatric and Neurodegenerative Disease in the Elderly: An Update
Neuropsychiatric disorders are common among elderly patients in long-term care facilities. Although dementia is most common, schizophrenia and schizoaffective disorder, delusional disorder, bipolar disorder, and Parkinson’s disease, as well as other psychiatric and neurodegenerative disorders, can also occur in this population. Our objective was to review the literature pertaining to the safety and efficacy of risperidone in elderly patients, the atypical antipsychotic with the longest history of use in this population. We identified original studies of risperidone in elderly patients through MEDLINE and CURRENT CONTENTS database searches. Additional material was identified via abstracts presented at national and international conferences. Published data from controlled and uncontrolled trials in elderly patients support the efficacy of risperidone in controlling behavioral and psychological symptoms of dementia, as well as treating psychotic symptoms associated with schizophrenia and other disorders with psychotic features. Limited data suggest that risperidone might also be useful for management of patients with delirium and Huntington’s disease. Risperidone was well tolerated in the elderly and associated with a low risk of movement disorders and anticholinergic effects. A recent change in the product information described an increased incidence of cerebrovascular events in some elderly and suggests the need for further investigations in this population. There is a substantial published database supporting safe and effective use of risperidone for treatment of psychosis, agitation, and aggression in elderly patients. Psychopharmacology Bulletin. 2003;37(4):116-132.
- 12 August 2025
- Published by MedWorks Media in Psychopharmacology Bulletin
- Vol. 37 (4) , 116-131
Risperidone in the Management of Psychiatric and Neurodegenerative Disease in the Elderly: An Update
Neuropsychiatric disorders are common among elderly patients in long-term care facilities. Although dementia is most common, schizophrenia and schizoaffective disorder, delusional disorder, bipolar disorder, and Parkinson’s disease, as well as other psychiatric and neurodegenerative disorders, can also occur in this population. Our objective was to review the literature pertaining to the safety and efficacy of risperidone in elderly patients, the atypical antipsychotic with the longest history of use in this population. We identified original studies of risperidone in elderly patients through MEDLINE and CURRENT CONTENTS database searches. Additional material was identified via abstracts presented at national and international conferences. Published data from controlled and uncontrolled trials in elderly patients support the efficacy of risperidone in controlling behavioral and psychological symptoms of dementia, as well as treating psychotic symptoms associated with schizophrenia and other disorders with psychotic features. Limited data suggest that risperidone might also be useful for management of patients with delirium and Huntington’s disease. Risperidone was well tolerated in the elderly and associated with a low risk of movement disorders and anticholinergic effects. A recent change in the product information described an increased incidence of cerebrovascular events in some elderly and suggests the need for further investigations in this population. There is a substantial published database supporting safe and effective use of risperidone for treatment of psychosis, agitation, and aggression in elderly patients. Psychopharmacology Bulletin. 2003;37(4):116-132.
- 12 August 2025
- Published by MedWorks Media in Psychopharmacology Bulletin
- Vol. 36 (3) , 5-21
Clinical Significance of Drug Binding, Protein Binding, and Binding Displacement Drug Interactions
Drugs widely used in clinical psychopharmacology, with few exceptions, are hepatically eliminated and circulate in the blood bound to plasma proteins. Often, the degree of binding is high (>90%). This fact has led to a widespread belief that such drugs may frequently participate in drug-binding interactions. The logic is as follows: coadministration of drugs can result in a highly bound drug displacing a less avidly bound drug from its binding sites. This leads to greater amounts of free, nonprotein-bound drug available for distribution to the sites of action. As free drug is a major determinant of pharmacologic effects, these drug interactions could result in toxicity and/or enhanced efficacy. This reasoning simplifies a complex situation where compensatory changes occur in the body to buffer the impact of drug-binding interactions. There are few examples where the above events have been documented to occur with psychoactive drugs leading to substantial clinical consequences. Although protein-binding displacement interactions are generally of minimal clinical significance, this is an assumption not based on evidence, but rather the lack of it. The purpose of this review is to examine some relevant aspects of drug-protein binding and draw conclusions for clinical practice about the significance of drug binding and drug-binding displacement interactions. Psychopharmacology Bulletin. 2002;36(3):5-21
- 12 August 2025
- Published by MedWorks Media in Psychopharmacology Bulletin
- Vol. 36 (3) , 5-21
Clinical Significance of Drug Binding, Protein Binding, and Binding Displacement Drug Interactions
Drugs widely used in clinical psychopharmacology, with few exceptions, are hepatically eliminated and circulate in the blood bound to plasma proteins. Often, the degree of binding is high (>90%). This fact has led to a widespread belief that such drugs may frequently participate in drug-binding interactions. The logic is as follows: coadministration of drugs can result in a highly bound drug displacing a less avidly bound drug from its binding sites. This leads to greater amounts of free, nonprotein-bound drug available for distribution to the sites of action. As free drug is a major determinant of pharmacologic effects, these drug interactions could result in toxicity and/or enhanced efficacy. This reasoning simplifies a complex situation where compensatory changes occur in the body to buffer the impact of drug-binding interactions. There are few examples where the above events have been documented to occur with psychoactive drugs leading to substantial clinical consequences. Although protein-binding displacement interactions are generally of minimal clinical significance, this is an assumption not based on evidence, but rather the lack of it. The purpose of this review is to examine some relevant aspects of drug-protein binding and draw conclusions for clinical practice about the significance of drug binding and drug-binding displacement interactions. Psychopharmacology Bulletin. 2002;36(3):5-21
- Open Access
- 13 February 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (4) , 311-316
Impact of artificial intelligence on future clinical pharmacy research and scholarship
Almost every facet of modern biomedical research involves artificial intelligence (AI). This ACCP commentary forecasts the role of AI in clinical pharmacy research and scholarship. The potential benefits/opportunities together with the limitations/challenges of AI are reviewed for stages of the scientific method including (1) developing the research question(s), study design, and execution; (2) data analysis; and (3) reporting and dissemination of clinical pharmacy research. Benefits and opportunities of AI in clinical pharmacy research include streamlining hypothesis generation and facilitating study design, overcoming limitations of traditional statistical analysis techniques, facilitating manuscript development and dissemination, and expediting peer review. Limitations and challenges of AI include the introduction of biases in subject recruitment; generation of false information, also known as “AI hallucinations”; concern of “black box” analyses that are difficult to validate; potential legal liabilities; lack of accountability; and the need for investigators to ensure the accuracy and integrity of AI‐generated content. In summary, rapid progress of AI capabilities has great potential to revolutionize and accelerate clinical pharmacy research and scholarship; however, it is also imperative to recognize and mitigate the challenges and limitations introduced by AI.
- 13 February 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (4) , 311-316
Open AccessImpact of artificial intelligence on future clinical pharmacy research and scholarship
Almost every facet of modern biomedical research involves artificial intelligence (AI). This ACCP commentary forecasts the role of AI in clinical pharmacy research and scholarship. The potential benefits/opportunities together with the limitations/challenges of AI are reviewed for stages of the scientific method including (1) developing the research question(s), study design, and execution; (2) data analysis; and (3) reporting and dissemination of clinical pharmacy research. Benefits and opportunities of AI in clinical pharmacy research include streamlining hypothesis generation and facilitating study design, overcoming limitations of traditional statistical analysis techniques, facilitating manuscript development and dissemination, and expediting peer review. Limitations and challenges of AI include the introduction of biases in subject recruitment; generation of false information, also known as “AI hallucinations”; concern of “black box” analyses that are difficult to validate; potential legal liabilities; lack of accountability; and the need for investigators to ensure the accuracy and integrity of AI‐generated content. In summary, rapid progress of AI capabilities has great potential to revolutionize and accelerate clinical pharmacy research and scholarship; however, it is also imperative to recognize and mitigate the challenges and limitations introduced by AI.
- Open Access
- 28 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (21) , 11570
Prenatal Opioid and Alcohol Exposures: Association with Altered Placental Serotonin Transporter Structure and/or Expression
Fetal exposures to many drugs of abuse, e.g., opioids and alcohol (EtOH), are associated with adverse neurodevelopmental problems in early childhood, including abnormalities in activity of the serotonin (5HT) transporter (SERT), which transports 5HT across the placenta. Little is known about the effects of these drugs on SERT expression. Pregnant women who used EtOH or opioids were compared to gestational age-matched controls using a structured questionnaire to determine prenatal substance exposure. Following elective pregnancy termination, placental membranous vesicles and exosomes were prepared from first and second trimester human placentas. Changes in EtOH- or opioid-exposed placental SERT expression and modifications were assessed by quantitative western blot. Novel SERT isoforms were sequenced and analyzed. Opioid-exposed but not EtOH-exposed maternal placentas showed SERT cleavage and formation of new SERT fragments (isoforms). Alcohol-exposed cases showed reduced SERT levels. Antibodies to the N-terminal SERT region did not recognize either of the two cleavage products, while antibodies to the central and C-terminal regions recognized both bands. The secondary band seen in the opioid group may represent a hypophosphorylated SERT fragment. These changes in SERT modifications and expression may result in altered fetal brain serotonergic neurotransmission, which could have neurodevelopmental implications.
- 28 October 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (21) , 11570
Open AccessPrenatal Opioid and Alcohol Exposures: Association with Altered Placental Serotonin Transporter Structure and/or Expression
Fetal exposures to many drugs of abuse, e.g., opioids and alcohol (EtOH), are associated with adverse neurodevelopmental problems in early childhood, including abnormalities in activity of the serotonin (5HT) transporter (SERT), which transports 5HT across the placenta. Little is known about the effects of these drugs on SERT expression. Pregnant women who used EtOH or opioids were compared to gestational age-matched controls using a structured questionnaire to determine prenatal substance exposure. Following elective pregnancy termination, placental membranous vesicles and exosomes were prepared from first and second trimester human placentas. Changes in EtOH- or opioid-exposed placental SERT expression and modifications were assessed by quantitative western blot. Novel SERT isoforms were sequenced and analyzed. Opioid-exposed but not EtOH-exposed maternal placentas showed SERT cleavage and formation of new SERT fragments (isoforms). Alcohol-exposed cases showed reduced SERT levels. Antibodies to the N-terminal SERT region did not recognize either of the two cleavage products, while antibodies to the central and C-terminal regions recognized both bands. The secondary band seen in the opioid group may represent a hypophosphorylated SERT fragment. These changes in SERT modifications and expression may result in altered fetal brain serotonergic neurotransmission, which could have neurodevelopmental implications.
- 16 September 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (9) , 696-697
The gray area of scientific adequacy
- 16 September 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (9) , 696-697
The gray area of scientific adequacy
- 5 May 2023
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (5) , 358
Current clinical pharmacology issues in pregnancy and pediatrics
- 5 May 2023
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (5) , 358
Current clinical pharmacology issues in pregnancy and pediatrics
- 1 January 2023
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (1) , 4-5
Reflections on the future of biomedical publishing
- 1 January 2023
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 43 (1) , 4-5
Reflections on the future of biomedical publishing
- 4 May 2020
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 40 (5) , 376-378
The Role of Scientific Publishing in the SARS‐CoV‐2 Pandemic
- 4 May 2020
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 40 (5) , 376-378
The Role of Scientific Publishing in the SARS‐CoV‐2 Pandemic